Original

Long term efficacy and toleration of topiramate in 44 children with resistant epilepsy

J.L. Herranz, R. Arteaga DOI: https://doi.org/10.33588/rn.2811.99117

OPEN ACCESS

Volumen 28 | Number 11 | Nº of views of the article 4.970 | Nº of PDF downloads 205 | Article publication date 01/06/1999

Download PDF Castellano Citation Search in PubMed

Share in:

Go to another issue

ABSTRACT

INTRODUCTION Topiramate (TPM) is a new antiepileptic drug with multiple modes of action which should theoretically represent a wide therapeutic spectrum. However, there is still little clinical experience of its use in children with epilepsy.

PATIENTS AND METHODS TPM was given during a period of 14.8±15.4 months, at an average dose of 6.6±2.5 mg/kg/day to 44 children with resistant epilepsy. They included 21 children with Lennox-Gastaut syndrome, 14 with partial epilepsy, 7 with multifocal epilepsy, one with polymorphic epilepsy and one with electrical changes during sleep.

RESULTS When TPM was associated with their treatment, a response of >50% reduction in epileptic crises was seen in 76% of the cases (85% with Lennox-Gastaut syndrome, 64% with partial epilepsy, 71% with multifocal epilepsy) and suppression of crises in 12% of the cases (5% with Lennox-Gastaut syndrome, 21% with partial epilepsy and 14% with multifocal epilepsy). The drug was well tolerated and only stopped because of side-effects in 4.5% of the cases. CONCLUSION. TPM is an antiepileptic drug with a broad therapeutic spectrum, good clinical efficacy in children and is well tolerated by them KeywordsAntiepileptic drugs Lennox-Gastaut syndrome Multifocal epilepsy Partial epilepsy Resistant epilepsy Topiramate CategoriesEpilepsias y síndromes epilépticos Neuropediatría

FULL TEXT (solo disponible en lengua castellana / Only available in Spanish)

Acceso directo al último número

Último Podcast

Original

Long term efficacy and toleration of topiramate in 44 children with resistant epilepsy